Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia

2009 ◽  
Vol 50 (5) ◽  
pp. 857-858 ◽  
Author(s):  
Emanuele Ammatuna ◽  
Chiara Sarlo ◽  
Licia Ottaviani ◽  
Micol Quaresima ◽  
Francesco Buccisano ◽  
...  
Blood ◽  
2002 ◽  
Vol 99 (10) ◽  
pp. 3742-3747 ◽  
Author(s):  
Rainer Hubmann ◽  
Josef D. Schwarzmeier ◽  
Medhat Shehata ◽  
Martin Hilgarth ◽  
Markus Duechler ◽  
...  

Members of the Notch family encode transmembrane receptors that modulate differentiation, proliferation, and apoptotic programs of many precursor cells, including hematopoietic progenitors. Stimulation of Notch causes cleavage followed by translocation of the intracellular domain (NotchIC) to the nucleus, where it activates transcription of CBF1 responsive genes. The aim of this study was to elucidate the mechanisms leading to the overexpression of CD23, a striking feature of B-cell chronic lymphocytic leukemia (B-CLL) cells. By electrophoretic mobility shift assays, we identified a transcription factor complex (C1) that binds sequence specific to one known and 4 newly identified putative CBF1 recognition sites in the CD23a core promoter region. With the use of Epstein-Barr virus (EBV)–infected B cells as a model for CBF1 mediated CD23a expression, C1 was found to be EBV inducible. Supershift assays revealed that the nuclear form of Notch2 is a component of C1 in B-CLL cells, supporting a model in which NotchIC activates transcription by binding to CBF1 tethered to DNA. Transient transfection of REH pre–B cells with an activated form of Notch2 induced endogenous CD23a, confirming thatCD23a is a target gene of Notch2 signaling. Finally, reverse transcription-polymerase chain reaction and kinetic analysis demonstrated that the Notch2 oncogene is not only overexpressed in B-CLL cells but might also be related to the failure of apoptosis characteristic for this disease. In conclusion, these data suggest that deregulation of Notch2 signaling is involved in the aberrant expression of CD23 in B-CLL.


1992 ◽  
Vol 176 (4) ◽  
pp. 1073-1081 ◽  
Author(s):  
J Cai ◽  
C Humphries ◽  
A Richardson ◽  
P W Tucker

B cell chronic lymphocytic leukemia (CLL) is the malignant, monoclonal equivalent of a human CD5+ B cell. Previous studies have shown that the VH and VL genes rearranged and/or expressed in CLL have few and apparently random mutations. However, in this study, we have found that the rearranged VH251 gene, one of the three-membered VH5 family, has extensive and selective mutations in B-CLL cells. Somatic mutation at the nucleotide level is 6.03% in B-CLLs whereas the somatic mutation levels are much lower in CD5+ and CD5- cord B cells, adult peripheral blood B cells, and Epstein-Barr virus-transformed CD5+ B cell lines (0.45, 0.93, and 1.92%, respectively). Complementary determining region 1 (CDR1) mutation in CLLs is particularly prevalent, and interchanges in CDRs often lead to acquisition of charge. Analysis of somatic mutations and mutations to charged residues demonstrated that the mutations in CLLs are highly selected.


2016 ◽  
Vol 9 (3) ◽  
pp. 113-120 ◽  
Author(s):  
Julie Morscio ◽  
Emilie Bittoun ◽  
Nathalie Volders ◽  
Eveline Lurquin ◽  
Iwona Wlodarska ◽  
...  

2018 ◽  
Vol 11 (2) ◽  
pp. 65-65
Author(s):  
Julie Morscio ◽  
Emilie Bittoun ◽  
Nathalie Volders ◽  
Eveline Lurquin ◽  
Iwona Wlodarska ◽  
...  

Cancer ◽  
2010 ◽  
Vol 116 (4) ◽  
pp. 880-887 ◽  
Author(s):  
Jeffrey J. Tarrand ◽  
Michael J. Keating ◽  
Apostolia M. Tsimberidou ◽  
Susan O'Brien ◽  
Rocco P. LaSala ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (10) ◽  
pp. e0140178 ◽  
Author(s):  
Ewelina Grywalska ◽  
Jacek Roliński ◽  
Marcin Pasiarski ◽  
Izabela Korona-Glowniak ◽  
Maciej Maj ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document